Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04051502 · ClinicalTrials.gov registry record · Early Phase 1

ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study

A Early Phase 1 study of Ovarian Cancer and Adnexal Mass, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
Early Phase 1
Development phase
48
Enrollment target
7
Study locations

NCT04051502: Completed Early Phase 1 study of Ovarian Cancer and Adnexal Mass, sponsored by Memorial Sloan Kettering Cancer Center.

NCT04051502 is a Early Phase 1 study of Ovarian Cancer and Adnexal Mass that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 48 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04051502, a Early Phase 1 study of Ovarian Cancer and Adnexal Mass, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
Early Phase 1
Development phase
48 participants
Enrollment target
7
Study locations

Study Summary

The purpose of this study is to find out how well ovarian sentinel lymph nodes (SLNs) can be identified with indocyanine green (ICG) dye during risk-reducing ovarian surgery.

Primary Outcome

Evaluate for dye uptake in the regional lymphatic channels, and in the pelvic and para-aortic nodes using infrared imaging.

Interventions

  • DRUG Method 1: Indocyanine green dye
  • DRUG Method 2: Indocyanine green dye
  • DRUG Method 3: Indocyanine green dye

Study Locations (7)

New York

  • Memorial Sloan Kettering Commack (Consent only) - Commack
  • Memorial Sloan Kettering Westchester (Consent only) - Harrison
  • Memorial Sloan Kettering Cancer Center - New York
  • Memorial Sloan Kettering Nassau (Consent only) - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge (Consent only) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (Consent only) - Middletown
  • Memorial Sloan Kettering Bergen (Consent only ) - Montvale

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2019-08-05
Est. Completion 2025-12-08
Phase Early Phase 1
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the finished NCT04051502 record still lists

NCT04051502 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (93% lower).

The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 3 interventions - of which Method 1: Indocyanine green dye is the first listed.

NCT04051502 lists 7 locations in 2 states (New York, New Jersey).

Frequently Asked Questions

What is clinical trial NCT04051502 about?

NCT04051502 is a clinical study titled "ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study". The purpose of this study is to find out how well ovarian sentinel lymph nodes (SLNs) can be identified with indocyanine green (ICG) dye during risk-reducing ovarian surgery.

What is the current status of trial NCT04051502?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 48 participants. The study started on 2019-08-05. Estimated completion is 2025-12-08.

What conditions does trial NCT04051502 study?

This clinical trial studies the following conditions: Ovarian Cancer, Adnexal Mass.

What interventions are being tested in trial NCT04051502?

The interventions under investigation include: Method 1: Indocyanine green dye (DRUG), Method 2: Indocyanine green dye (DRUG), Method 3: Indocyanine green dye (DRUG).

Who is sponsoring clinical trial NCT04051502?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04051502 being conducted?

This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04051502's enrollment target sits among peer trials

48 213th of 322 higher than 107 of 322 other Ovarian Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04051502, the US trial registry maintained by the National Library of Medicine. NCT04051502 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.